Learn more about our currently enrolling clinical studies at dawesfretzinresearch.com/patients

Use the links to the right to view more information about clinical studies by year.

Rosacea
Sponsor: Cutanea Life Sciences, Inc.
A Phase 2, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Three Once-Daily CLS001 Topical Gels Versus Vehicle Administered for 12 Weeks to Subjects With Papulopustular Rosacea. -Details
February 2013 to Present

Allergy
Sponsor: Merck and Co., Inc.
Time and Motion Study of Allergen Immunotherapy in the Usual Care Environment in the United States and Canada
June 2012 to Present

Atopic Dermatitis
Sponsor: Anacor Pharmaceuticals, Inc.
An Open-Label Study to Determine the Safety, tolerability, and Pharmacokinetic Profile of AN2728 Ointment in Adolescents with Atopic Dermatitis
May 2012 to Present

Acne
Sponsor: Warner Chilcott
A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Different doses of a Novel Tetracycline, Compared to Placebo in Treatment of Facial Acne Vulgaris
May 2012 to Present

Psoriasis
Sponsor: Leo Pharmaceuticals
A phase 2 study comparing treatment with LEO 90100 with calcipotriol plus betamethasone ointment, LEO 90100 vehicle and ointment vehicle in subjects with psoriasis vulgaris
May 2012 to Present

Psoriasis
Sponsor: Stiefel Laboratories, Inc.
A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Calcipotriene Foam, 0.005%, Applied Under Maximal-Use Conditions in Adolescent Subjects (Ages 12 to 16 Years) with Plaque Psoriasis
May 2012 to Present

Rosacea
Sponsor: Galderma Research and Development, Inc.
A Phase 3 randomized, double-blind, 12-week vehicle-controlled, parallel-group study assessing the efficacy and safety of CD5024 1% cream versus vehicle cream in subjects with papulopustular rosacea, followed by a 40-week investigator-blinding extension comparing the long-term safety of CD5024 1% cream versus azelaic acid 15% gel
March 2012 to Present

Psoriasis
Sponsor: Eli Lilly and Co., Inc.
A Multicenter Study with a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance dosing Period and a Long-Term Extension Period to Evaluate the Efficacy and Safey of LY2439821 in Patients with Moderate-to-Severe Plaque Psoriasis
February 2012 to Present

VZV Vaccine
Sponsor: Merck and Co., Inc.
A Phase II Randomized, Placebo-Controlled Clinical Trail to Study the Safety and Immunogenicity of V212 in Adult Patients with Autoimmune Disease
February 2012 to Present

Psoriasis
Sponsor: Janssen Research and Development, Inc.
A Phase 2 Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO 1959 for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis
January 2012 to Present

Cutaneous Lupus Erythematosus
Sponsor: Pfizer
A Randomized, Subject and Investigator-Blilnded, (Sponsor-Open), Placebo-Controlled dose Excalation Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Multiple Doses of PD 0360324 in Subjects with Active Cutaneous Lupus Erythematosus. -Details
January 2012 to Present

Asthma
Sponsor: GlaxoSmithKline
A Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination versus Inhaled Fluticasone Propionate in the Treatment of Adolescent and Adult Subjects with Asthma. -Details
January 2012 to Present

Psoriasis
Sponsor: Novartis
A randomized, double-blind, multicenter study of subcutaneous secukinumab, assessing Psoriasis Area and Severity Index (PASI) response and maintenance of response in subjects with moderate to severe chronic plaque-type psoriasis on either a fixed dose regimen or on a retreatment at start of relapse regimen. -Details
October 2011 to Present

Atopic Dermatitis
Sponsor: Novartis
A first-in-human study to evaluate safety and tolerability of repeated topical administrations of BPR277 ointment in healthy volunteers, and safety, tolerability, and preliminary efficacy of multiple topical administrations of BPR277 in patients with atopic dermatitis and Netherton syndrome.
October 2011 to Present

Psoriasis
Sponsor: Novartis
A randomized, double-blind, double-dummy, placebo controlled, multicenter study of subcutaneous secukinumab to demonstrate efficacy after twelve weeks of treatment, compared to placebo and etanercept, and to assess the safety, tolerability and long-term efficacy up to one year in subjects with moderate to severe chronic plaque-type psoriasis.
September 2011 to Present

Onychomycosis
Sponsor: Hisamitsu Pharmaceutical Co., Inc.
A Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo-Controlled Study of the Safety and Efficacy of HTU-520 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenail
June 2011 to Present

Cutaneous Lupus Erythematosus
Sponsor: Celgene Corporation
A Phase 2, Pilot, Multicenter, Sequential, Ascending Dose Study to Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus
June 2011 to Present

Psoriasis
Sponsor: Pfizer
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis. This one-year study will also evaluate the safety and tolerability of CP-690,550 versus placebo.
May 2011 to Present

Chronic Idiopathic Urticaria
Sponsor: Genentech
The study is a global Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of omalizumab administered subcutaneously as an add-on therapy for the treatment of adolescent and adult patients aged 12-75 who have been diagnosed with refractory CIU and who remain symptomatic despite standard-dosed H1 antihistamine treatment.
April 2011 to Present

Psoriatic Arthritis
Sponsor: Celgene Corporation
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Two Doses Of Apremilast (CC-10004) In Subjects With Active Psoriatic Arthritis And A Qualifying Psoriasis Lesion. -Details
January 2011 to Present

Psoriatic Arthritis
Sponsor: Centocor, Inc.
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis and Previously Treated With Biologic Anti-TNF Agent(s)
November 2010 to Present

Psoriasis
Sponsor: Astellas Pharma Inc.
APPLES: A Prospective Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis
June 2010 to Present

Atopic Dermatitis
Sponsor: Novartis
A Prospective 10 Year Observational Registry of Pediatric Subjects (Age Greater Than or Equal to Two to Age Less Than or Equal to 17 Years) With Atopic Dermatitis Who Have Used Pimecrolimus 1% Cream (PEER Registry)
March 2010 to Present

Psoriatic Arthritis
Sponsor: Centocor, Inc.
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis
February 2010 to Present

Psoriasis
Sponsor: Abbott Laboratories
A 10-Year, Post-marketing, Observational Study of HUMIRA® (Adalimumab) in Patients With Chronic Plaque Psoriasis (Ps) (ESPRIT Registry)
November 2008 to Present

Psoriasis
Sponsor: Centocor Ortho Biotech Services, LLC.
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics (PSOLAR Registry)
May 2008 to Present

Psoriasis
Sponsor: Abbott Laboratories
A Phase III Multicenter, Open-Label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects who Completed a Preceding Psoriasis Study With XXXXX (M016)
March 2008 to Present

Arthritis with Cardiovascular Disease
Sponsor: Pfizer
A Randomized, Double Blind, Parallel-Group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen.
December 2006 to Present

Psoriasis
Sponsor: Amgen, Inc.
Observational Post-Marketing Safety Surveillance Registry of Enbrel (Etanercept) for Treatment of Psoriasis. (OBSERVE) -Details
July 2006 to Present